Andrew K. Balo - 10 Mar 2023 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
EVP Regulatory Strategy Clinic
Signature
By: Jereme Sylvain For: Andrew K Balo
Issuer symbol
DXCM
Transactions as of
10 Mar 2023
Net transactions value
-$1,300,026
Form type
4
Filing time
14 Mar 2023, 16:45:58 UTC
Previous filing
10 Mar 2022
Next filing
28 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Disposed to Issuer $364,832 -3,275 -5.2% $111.40 59,303 10 Mar 2023 Direct F1, F2
transaction DXCM Common Stock Disposed to Issuer $267,915 -2,405 -4.1% $111.40 56,898 10 Mar 2023 Direct F1, F2
transaction DXCM Common Stock Disposed to Issuer $667,280 -5,990 -11% $111.40 50,908 10 Mar 2023 Direct F1, F2
holding DXCM Common Stock 30,212 10 Mar 2023 by Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Andrew K. Balo is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
F3 Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.